[go: up one dir, main page]

MX2010003315A - Derivados de benzoquinona e3330 en combinacion con agentes quimioterapeuticos para el tratamiento de cancer y angiogenesis. - Google Patents

Derivados de benzoquinona e3330 en combinacion con agentes quimioterapeuticos para el tratamiento de cancer y angiogenesis.

Info

Publication number
MX2010003315A
MX2010003315A MX2010003315A MX2010003315A MX2010003315A MX 2010003315 A MX2010003315 A MX 2010003315A MX 2010003315 A MX2010003315 A MX 2010003315A MX 2010003315 A MX2010003315 A MX 2010003315A MX 2010003315 A MX2010003315 A MX 2010003315A
Authority
MX
Mexico
Prior art keywords
cancer
angiogenesis
apel
ref
treatment
Prior art date
Application number
MX2010003315A
Other languages
English (en)
Inventor
R Kelley Mark
Original Assignee
Univ Indiana Res & Tech Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Indiana Res & Tech Corp filed Critical Univ Indiana Res & Tech Corp
Publication of MX2010003315A publication Critical patent/MX2010003315A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/201—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having one or two double bonds, e.g. oleic, linoleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/203—Retinoic acids ; Salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A61K31/282—Platinum compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Inorganic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Endocrinology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Epoxy Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)

Abstract

Se describen nuevos métodos para el tratamiento terapéutico de cáncer y angiogénesis. La enzima Apel/Ref-1, mediante su función de reducción-oxidación mejora la actividad de unión a DNA de factores de transcripción que están asociados con el progreso de cáncer. La presente invención describe el uso de agentes para inhibir de manera selectiva la función de reducción-oxidación de Apel/Ref-1 y reducir de este modo el crecimiento, supervivencia, migración y metástasis de células tumorales. Además, se muestra que la actividad inhibitoria de Apel/Ref-1 aumenta los efectos terapéuticos de otros productos terapéuticos y protege a las células normales contra la toxicidad. Además, se muestra que la inhibición de Apel/Ref-1 disminuye la angiogénesis, para el uso en el tratamiento de cáncer así como otras condiciones patológicas de las cuales es un componente la angiogénesis alterada.
MX2010003315A 2007-09-26 2008-09-22 Derivados de benzoquinona e3330 en combinacion con agentes quimioterapeuticos para el tratamiento de cancer y angiogenesis. MX2010003315A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US97539607P 2007-09-26 2007-09-26
US98956607P 2007-11-21 2007-11-21
PCT/US2008/077210 WO2009042542A1 (en) 2007-09-26 2008-09-22 Benzoquinone derivative e3330 in combination with chemotherapeutic agents for the treatment of cancer and angiogenesis

Publications (1)

Publication Number Publication Date
MX2010003315A true MX2010003315A (es) 2011-03-15

Family

ID=39951652

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2010003315A MX2010003315A (es) 2007-09-26 2008-09-22 Derivados de benzoquinona e3330 en combinacion con agentes quimioterapeuticos para el tratamiento de cancer y angiogenesis.

Country Status (13)

Country Link
US (6) US9089605B2 (es)
EP (4) EP2203161B1 (es)
JP (4) JP5628674B2 (es)
KR (2) KR101572688B1 (es)
AU (5) AU2008304619C1 (es)
BR (1) BRPI0817293A2 (es)
CA (2) CA2700365C (es)
ES (2) ES2675951T3 (es)
IL (1) IL204675A0 (es)
MX (1) MX2010003315A (es)
RU (1) RU2510270C2 (es)
WO (2) WO2009042542A1 (es)
ZA (1) ZA201002246B (es)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2203161B1 (en) * 2007-09-26 2018-05-09 Indiana University Research and Technology Corporation Quinone derivatives, pharmaceutical compositions, and uses thereof
US11331294B2 (en) 2007-09-26 2022-05-17 Indiana University Research And Technology Corporation Benzoquinone derivative E3330 in combination with chemotherapeutic agents for the treatment of bladder cancer
US9567346B2 (en) * 2010-10-29 2017-02-14 Life Technologies Corporation Biotin derivatives
US9517244B2 (en) 2011-04-22 2016-12-13 University Of Florida Research Foundation, Inc. Therapeutic combinations for use in neoplasia
JP6109821B2 (ja) * 2011-05-26 2017-04-05 インディアナ ユニバーシティー リサーチ アンド テクノロジー コーポレーションＩｎｄｉａｎａ Ｕｎｉｖｅｒｓｉｔｙ Ｒｅｓｅａｒｃｈ Ａｎｄ Ｔｅｃｈｎｏｌｏｇｙ Ｃｏｒｐｏｒａｔｉｏｎ Ａｐｅ１媒介疾患を処置するためのキノン化合物
WO2012167122A1 (en) 2011-06-03 2012-12-06 Indiana University Research And Technology Corporation Compounds, compositions and methods for treating oxidative dna damage disorders
WO2013021953A1 (ja) * 2011-08-05 2013-02-14 帝人株式会社 縮合多環芳香族化合物、芳香族重合体、及び芳香族化合物の合成方法
US9624235B2 (en) * 2012-01-31 2017-04-18 University of Pittsburgh—of the Commonwealth System of Higher Education Compounds and methods for inhibition of AP endonuclease-1/redox factor-1 (HAPE1) activity
ES2689665T3 (es) 2012-03-14 2018-11-15 Indiana University Research And Technology Corporation Compuestos y métodos para tratar la leucemia
WO2013180217A1 (ja) 2012-05-30 2013-12-05 日本ゼオン株式会社 重合性化合物、重合性組成物、高分子、及び光学異方体
CN104603165B (zh) 2012-07-09 2017-04-26 日本瑞翁株式会社 聚合性化合物、聚合性组合物、高分子、光学各向异性体及聚合性化合物的制备方法
US9995865B2 (en) 2012-10-22 2018-06-12 Zeon Corporation Phase difference plate, circularly polarizing plate, and image display device
WO2015025793A1 (ja) 2013-08-22 2015-02-26 日本ゼオン株式会社 重合性化合物、重合性組成物、高分子、及び光学異方体
KR102315630B1 (ko) 2013-10-31 2021-10-20 제온 코포레이션 중합성 화합물, 중합성 조성물, 고분자, 및 광학 이방체
KR101612097B1 (ko) 2015-01-07 2016-04-12 충남대학교산학협력단 아세틸화된 산화환원조절단백-1의 제조방법 및 이를 함유하는 유방암 예방 및 치료용 조성물
CN107406769B (zh) 2015-03-19 2021-01-29 日本瑞翁株式会社 液晶性组合物、相位差层的制造方法和圆偏振片
WO2016186853A1 (en) * 2015-05-21 2016-11-24 Indiana University Research & Technology Corporation Methods of targeting ape1/ref-1 to inhibit hypoxia signaling genes
JP6975040B2 (ja) 2015-05-28 2021-12-01 日本ゼオン株式会社 円偏光分離フィルムの製造方法
KR20170052345A (ko) * 2015-11-04 2017-05-12 충남대학교산학협력단 환원형 산화환원조절단백-1를 함유하는 염증 예방 및 치료용 약학 조성물
JPWO2017110638A1 (ja) 2015-12-22 2018-10-11 日本ゼオン株式会社 液晶性組成物、液晶硬化層及びその製造方法、並びに、光学フィルム
US10669482B2 (en) 2016-03-08 2020-06-02 Zeon Corporation Liquid crystal composition, liquid crystal cured layer, and method for producing said liquid crystal cured layer
EP3573606A4 (en) * 2017-01-25 2020-11-25 Indiana University Research and Technology Corporation PROPHYLAXIS AND TREATMENT OF ACUTE MYELOID LEUKEMIA
US20190160034A1 (en) * 2017-03-20 2019-05-30 Indiana University Research And Technology Corporation Use of ape1/ref-1 inhibitors in combination therapies for treatment of cancer
CN110392850A (zh) 2017-03-24 2019-10-29 日本瑞翁株式会社 液晶固化膜及其制造方法
EP3605167A4 (en) 2017-03-24 2020-12-09 Zeon Corporation LIQUID CRYSTAL COMPOSITION, LIQUID CRYSTAL HARDENED FILM AND METHOD FOR MANUFACTURING THEREOF
EP3440047A4 (en) * 2017-04-17 2020-04-01 Indiana University Research & Technology Corporation PREVENTING AND REVERSING INFLAMMATION-INSPECTED DNA DAMAGE
WO2018232238A1 (en) * 2017-06-16 2018-12-20 Indiana University Research And Technology Corporation Therapeutic agent for tuberous sclerosis complex (tsc)
CN111936459B (zh) * 2018-02-08 2023-06-20 印第安纳大学研究与技术公司 通过新型ape1/ref-1抑制剂靶向于眼部疾病
CN108440271A (zh) * 2018-04-03 2018-08-24 中山大学 一种6-甲氧基萘嵌苯酮类化合物的制备方法
JP2022513193A (ja) * 2018-12-17 2022-02-07 インディアナ ユニバーシティー リサーチ アンド テクノロジー コーポレーション 消化管障害及びその症状の治療
KR20240049212A (ko) * 2021-04-30 2024-04-16 오큐파이어 파마, 인크. 당뇨병성 망막병증 및 관련 병태의 치료 방법 및 조성물
EP4587003A2 (en) 2022-09-14 2025-07-23 Opus Genetics, Inc. Salts and esters of apx3330 and therapeutic uses thereof
WO2025147565A1 (en) * 2024-01-05 2025-07-10 Indiana University Research And Technology Corporation Treatment of necrotizing enterocolitis and symptoms thereof
WO2025194083A1 (en) * 2024-03-14 2025-09-18 Opus Genetics, Inc. Compositions comprising an apx3330 hemicalcium salt monohydrate and therapeutic uses thereof

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3438998A (en) * 1964-10-05 1969-04-15 Research Corp Antibiotic lambertellin and method for production
JPS51128932A (en) * 1975-04-30 1976-11-10 Takeda Chem Ind Ltd Organic compounds
JPS58177934A (ja) * 1982-04-13 1983-10-18 Takeda Chem Ind Ltd ベンゾキノン誘導体
FI102273B1 (fi) * 1989-09-11 1998-11-13 Eisai Co Ltd Kinonijohdannaiset, niiden valmistaminen ja niiden farmakologinen käyttö
US5629327A (en) * 1993-03-01 1997-05-13 Childrens Hospital Medical Center Corp. Methods and compositions for inhibition of angiogenesis
US6228879B1 (en) * 1997-10-16 2001-05-08 The Children's Medical Center Methods and compositions for inhibition of angiogenesis
JPH07291859A (ja) * 1994-04-28 1995-11-07 Eisai Co Ltd 転写因子活性阻害剤
AU3386597A (en) * 1996-06-11 1998-01-07 Advanced Research And Technology Institute, Inc. Methods and compositions for the use of apurinic/apyrimidinic endonucleases
US6406917B1 (en) * 1996-06-11 2002-06-18 Advanced Research And Technology Institute Methods and compositions for the use of apurinic/apyrimidinic endonucleases
EP0813866A3 (en) * 1996-06-17 1999-01-20 Eisai Co., Ltd. Therapeutic agent for joint diseases
FR2757860B1 (fr) * 1996-12-27 1999-04-23 Oxis International Sa Composes organoselenies cycliques, leur preparation et leurs utilisations, notamment therapeutiques
US5849793A (en) 1997-08-15 1998-12-15 The Picower Institute For Medical Research HIV matrix protein tyrosine position 29 pocket binders
NZ515711A (en) 1999-06-24 2004-01-30 Pharmacia Corp Combination of tumors necrocis factor (TNF) antagonists and COX-2 inhibitors for the treatment of inflammation
CA2441228A1 (en) * 2001-03-23 2002-10-03 Aphton Corporation Combination treatment of pancreatic cancer
JP4485744B2 (ja) * 2001-04-05 2010-06-23 トレント・ファーマシューティカルズ・リミテッド 老化−関連及び糖尿病性血管性合併症のための複素環式化合物
US20030229004A1 (en) * 2002-03-20 2003-12-11 Pangene Corporation Modulation of tumor cells using BER inhibitors in combination with a sensitizing agent and DSBR inhibitors
WO2003090681A2 (en) * 2002-04-24 2003-11-06 Research Development Foundation SYNERGISTIC EFFECTS OF NUCLEAR TRANSCRIPTION FACTOR NF-κB INHIBITORS AND ANTI-NEOPLASTIC AGENTS
WO2005000900A1 (en) * 2003-05-30 2005-01-06 Genentech, Inc. Treatment with anti-vegf antibodies
US20060024691A1 (en) * 2004-03-25 2006-02-02 Buck Institute For Age Research Novel pathways in the etiology of cancer
EP2203161B1 (en) 2007-09-26 2018-05-09 Indiana University Research and Technology Corporation Quinone derivatives, pharmaceutical compositions, and uses thereof

Also Published As

Publication number Publication date
EP2203161B1 (en) 2018-05-09
AU2008304619A1 (en) 2009-04-02
US20180325853A1 (en) 2018-11-15
ES2675951T3 (es) 2018-07-13
ZA201002246B (en) 2016-02-24
JP5628674B2 (ja) 2014-11-19
RU2010113569A (ru) 2011-11-10
AU2015268612A1 (en) 2016-01-07
AU2008304619B2 (en) 2015-09-24
WO2009042544A1 (en) 2009-04-02
EP3725309B1 (en) 2022-11-23
CA2700274C (en) 2017-08-22
US20100285008A1 (en) 2010-11-11
JP2015017091A (ja) 2015-01-29
CA2700365A1 (en) 2009-04-02
EP3299015A1 (en) 2018-03-28
KR20150038712A (ko) 2015-04-08
AU2018256605A1 (en) 2018-11-22
US9040505B2 (en) 2015-05-26
US10058523B2 (en) 2018-08-28
AU2008304619C1 (en) 2020-06-04
CA2700274A1 (en) 2009-04-02
KR101689796B1 (ko) 2016-12-27
AU2017203131C1 (en) 2020-06-04
US9089605B2 (en) 2015-07-28
BRPI0817293A2 (pt) 2015-06-16
US20150265564A1 (en) 2015-09-24
AU2017203131A1 (en) 2017-06-01
JP2015212293A (ja) 2015-11-26
JP2010540545A (ja) 2010-12-24
US20190231728A1 (en) 2019-08-01
ES2653855T3 (es) 2018-02-09
JP2010540544A (ja) 2010-12-24
AU2018256605C1 (en) 2020-07-02
EP2203162A1 (en) 2010-07-07
AU2020200585A1 (en) 2020-02-13
EP2203162B1 (en) 2017-11-08
WO2009042542A1 (en) 2009-04-02
JP5646327B2 (ja) 2014-12-24
IL204675A0 (en) 2010-11-30
RU2510270C2 (ru) 2014-03-27
AU2015268612B2 (en) 2017-02-23
CA2700365C (en) 2016-07-05
EP2203161A1 (en) 2010-07-07
KR101572688B1 (ko) 2015-11-27
KR20100084522A (ko) 2010-07-26
EP3725309A1 (en) 2020-10-21
AU2018256605B2 (en) 2019-10-31
AU2017203131B2 (en) 2018-08-02
US20220184016A1 (en) 2022-06-16
US20100297113A1 (en) 2010-11-25

Similar Documents

Publication Publication Date Title
AU2018256605A1 (en) Benzoquinone Derivative E3330 in Combination with Chemotherapeutic Agents for the Treatment of Cancer and Angiogenesis
Ferbeyre et al. The role of Stat5 transcription factors as tumor suppressors or oncogenes
NZ603932A (en) Treatment of metastatic stage prostate cancer with degarelix
WO2008134474A3 (en) Compositions and methods including cell death inducers and procaspase activation
WO2006138511A3 (en) Use of hif 1alfa modulators for treatment of cancer
EP2495324A3 (en) Cancer cell-specific apoptosis-inducing agents that target chromosome stabilization-associated genes
WO2013093508A3 (en) Wnt pathway inhibitors
WO2008015383A8 (en) Bmp-9 and bmp-10 and their use in breast and prostate cancer therapies
MY163477A (en) Pyrimidinyl-pyridazinone derivatives
GB0421900D0 (en) Inhibition of tumour cell migration
WO2005118824A8 (en) Methods and compositions for the inhibition of gene expression
MX365074B (es) Terapia contra el cancer que utiliza anticuerpos dirigidos a la cldn6 objetivo in vivo.
WO2007098611A8 (en) Compositions for treatment of cancer
WO2005116259A3 (en) Use of gene expression profiling to predict survival in cancer patient
GB201001602D0 (en) Oligopeptidic compounds and uses therof
WO2006001956A3 (en) Compositions for inhibiting cell growth and inducing apoptosis in cancer cells and methods of use thereof
WO2009070244A3 (en) Methods for inhibiting fascin
WO2009114703A3 (en) Combination therapy for the treatment of cancer
WO2012006181A3 (en) Compositions and methods for inhibiting oncogenic micrornas and treatment of cancer
WO2007065010A3 (en) Anti-angiogenesis compounds
UA84954C2 (ru) Конденсированные пиримидоны, пригодные для лечения и профилактики злокачественного новообразования
WO2006133361A3 (en) Use of gene expression profiling to predict survival in cancer patient
WO2005086971A3 (en) Anti-metastatic ability of mibefradil and gadolinium
WO2011122859A3 (ko) 뇌종양의 재발 가능성 및 생존 예후 예측용 조성물 및 이를 포함하는 키트
WO2006113367A3 (en) Methods, compounds and compositions with genotype selective anticancer activity

Legal Events

Date Code Title Description
FA Abandonment or withdrawal